Skip to main content
OpenTrials
Completed

NCT Number: NCT01813448

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of single and multiple ascending doses of fidaxomicin in healthy subjects. This study will also compare the safety, tolerability and PK of single and multiple doses of fidaxomicin in healthy Japanese and Caucasian subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pharmacokinetics of Fidaxomicin Healthy Subjects

Age range

20 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Parexel

Glendale, California, 91206, United States

About this study

Eligible subjects will check into the unit on Day-2 and remain confined to the clinical unit until Day 17.

Cohorts 2 and 3, which may run in parallel, will only be enrolled after review of the available safety data of Cohort 1 by the Safety Review Team.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at Screening and continuing throughout the study period and for 90 days after final study drug administration
  • Male subject must not donate sperm starting at Screening and throughout the study period and for at least 90 days after final study drug administration

Inclusion criteria

for Japanese Subjects

  • The subject is a healthy Japanese male who maintains the Japanese lifestyle, including diet and has a body mass index (BMI) of 18.0 to 28.0 kg/m2, inclusive.

Inclusion criteria

for Caucasian Subjects

  • The subject is a healthy Caucasian male and has a BMI of 18.0 to 32.0 kg/m2, inclusive

Exclusion criteria

  • The subject has any clinically significant disease history
  • The subject has a history of or current C.difficile infection or history of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (history of appendectomy, hernia repair, and/or cholecystectomy is permitted)
  • The subject has any clinically significant abnormality
  • The subject has a resting (i.e., seated for 5 minutes) pulse <40 or >90 beats per minute (bpm) at Screening or Day -2
  • The subject has hypertension (defined as seated systolic blood pressure [SBP] >140 mmHg or seated diastolic blood pressure [DBP] >90 mmHg) or hypotension (defined as seated SBP <90 mmHg or seated DBP <50 mmHg) at Screening or Day -2
  • The subject has/had a symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to clinic check-in on Day -2
  • The subject has a history of chronic diarrhea or constipation
  • The subject has a positive result for hepatitis C antibodies or hepatitis B surface antigen at Screening or has a known positive history of human immunodeficiency virus (HIV)
  • The subject has a known or suspected allergy or hypersensitivity to any of the components of fidaxomicin, the macrolide antibacterial class of compounds, or a history of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reactions

Treatment and study plan

Fidaxomicin

Drug

oral

Other names: OPT-80, Dificlir, Dificid

Placebo

Drug

oral

Primary outcomes

  1. Pharmacokinetics (PK) of fidaxomicin in plasma (single dose): Lag time (tlag)

    Time frame: Days 1-5 (14 times)

  2. PK of fidaxomicin plasma (single dose): Time to attain maximum concentration (tmax)

    Time frame: Days 1-5 (14 times)

  3. PK of fidaxomicin in plasma (single dose): Maximum Concentration (Cmax)

    Time frame: Days 1-5 (14 times)

  4. PK of fidaxomicin in plasma (single dose): Area Under the Plasma Concentration - Time Curve (AUC) from Time Zero to Time of Last Measurable Concentration (AUClast)

    Time frame: Days 1-5 (14 times)

  5. PK of fidaxomicin in plasma (single dose): AUC - Time Curve from Time Zero to Infinity (aucinf)

    Time frame: Days 1-5 (14 times)

  6. PK of fidaxomicin in plasma (single dose): AUC - Time Curve from Time Zero to 12 hours (AUC 0-12h)

    Time frame: Days 1-5 (14 times)

  7. PK of fidaxomicin in plasma (single dose): Total Body Clearance after Single Dose (CL/F)

    Time frame: Days 1-5 (14 times)

  8. PK of fidaxomicin in plasma (single dose): Apparent Volume of Distribution During Terminal Phase (Vz/F)

    Time frame: Days 1-5 (14 times)

  9. PK of fidaxomicin in plasma (last dose): Apparent Volume of Distribution During Terminal Phase (Vz/F)

    Time frame: Days 15-17 (11 times)

  10. PK of fidaxomicin in plasma (single dose): Apparent Terminal elimination Half-life (t 1/2)

    Time frame: Days 1-5 (14 times)

    Single Dose

  11. PK of fidaxomicin in plasma (last dose): Apparent Terminal elimination Half-life (t 1/2)

    Time frame: Days 15-17 (11 times)

    Single Dose

  12. PK of fidaxomicin in plasma (single dose): Trough levels

    Time frame: Days 6, 7, 10, and 12 (pre-morning dose)

  13. PK of fidaxomicin in plasma (last dose): tmax at Steady State (tmax, ss)

    Time frame: Days 15-17 (11 times)

    Last Dose

  14. PK of fidaxomicin in plasma (last dose): Cmax at Steady State (Cmax, ss)

    Time frame: Days 15-17 (11 times)

    Last Dose

  15. PK of fidaxomicin in plasma (last dose): AUC Over the dosing Interval (AUCtau)

    Time frame: Days 15-17 (11 times)

  16. PK of fidaxomicin in plasma (last dose): CL/F at Steady State (CL/F ss)

    Time frame: Days 15-17 (11 times)

  17. PK of fidaxomicin in plasma (last dose): Peak: Trough Ratio (PTR)

    Time frame: Days 15-17 (11 times)

  18. PK of fidaxomicin in plasma (last dose): Accumulation Ratio (Racc)

    Time frame: Days 15-17 (11 times)

  19. PK of fidaxomicin in plasma (last dose): Pre-dose Plasma Concentration Determined Directly from the Concentration-Time Profile (Ctrough)

    Time frame: Days 15-17 (11 times)

  20. PK of fidaxomicin in urine (last dose): Cumulative Amount of Drug Excreted in the urine from Time Zero to Time of Last Measurable Concentration (Aelast)

    Time frame: Days 1-5 (6 times)

  21. PK of fidaxomicin in urine (single dose): Percent Fraction of Administered Drug Excreted Unchanged in the urine from Time Zero to Time of Last Measurable Concentration (% Aelast )

    Time frame: Days 1-5 (6 times)

  22. PK of fidaxomicin in urine (single dose): Cumulative Amount of Drug Excreted in the Urine from time Zero to Infinity after Single Dose (Aeinf)

    Time frame: Days 1-5 (6 times)

  23. PK of fidaxomicin in urine (single dose): Percent Fraction of administered drug excreted unchanged in the urine from time Zero to Infinity after Single Dose (% Aeinf)

    Time frame: Days 1-5 (6 times)

  24. PK of fidaxomicin in urine (single dose): Renal Clearance (CL/R

    Time frame: Days 1-5 (6 times)

  25. PK of fidaxomicin in urine (last dose): Cumulative Amount of Drug Excreted in the urine over the dosing Interval at Steady State (Aetau)

    Time frame: Day 15 (1 time)

  26. PK of fidaxomicin in urine (last dose): Percent Fraction of Administered Drug Excreted Unchanged in the Urine over the Dosing Interval at Steady State (% Aetau)

    Time frame: Day 15 (1 time)

  27. PK of fidaxomicin in urine (last dose): Renal Clearance at Steady State (CLR,ss)

    Time frame: Day 15 ( 1 time)

  28. PK of fidaxomicin in feces (single dose): Amount of Drug Excreted in the Feces (Ae)

    Time frame: Days 1-5 (5 times)

  29. PK of fidaxomicin in feces (last dose): Amount of Drug Excreted in the Feces (Ae)

    Time frame: Days 15-17 (first bowel movement (BM) following the last dose to be collected)

  30. PK of fidaxomicin in feces (single dose): Percent Fraction of Administered Drug Excreted Unchanged in the Feces (%Ae)

    Time frame: Days 1-5 (5 times)

  31. PK of fidaxomicin in feces (last dose): Percent Fraction of Administered Drug Excreted Unchanged in the Feces (%Ae)

    Time frame: Days 15-17 (first BM following the last dose to be collected)

Sponsors and collaborators

Lead sponsor

Astellas Pharma Global Development, Inc.

Industry

Collaborators

  • Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Registry information

Official study title

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects

Important dates

Study start
2013
Primary completion
2013
Study completion
2013
First posted
Mar 19, 2013
Registry last updated
May 21, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.